CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 15 No. 11
Pages: 1  2  3  
Next
 

Neuropathic Cancer Pain: The Role of Adjuvant Analgesics

By John T. Farrar, MD, MSCC
Attending Neurologist, Pain Management Center, Senior Scholar, Center for Clinical Epidemiology and Biostatistics, Adjunct Assistant Professor of Epidemiology and Anesthesiology, University of Pennsylvania, Health System, Philadelphia, Pennsylvania
Russell K. Portenoy, MD
Chairman, Department of Pain, Medicine and Palliative Care, Beth Israel Medical Center, Professor of Neurology, Albert Einstein College of Medicine, New York, New York

| November 1, 2001
Neuropathic pain may be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. This pathophysiologic label is typically applied when the painful symptom is associated with an overt injury to neural structures, is part of a recognized syndrome, or has a dysesthetic quality (usually burning, shooting, or electrical). Most neural injury does not lead to clinically important neuropathic pain, but sometimes even a small degree of tissue injury can precipitate severe pain. In the cancer population, neuropathic pain is often related to compression, direct neoplastic invasion of the peripheral nerves or spinal cord, or to a neuropathy caused by chemotherapy. To manage neuropathic pain in this population, nonopioid adjuvant drugs that are neuroactive or neuromodulatory are often needed to complement opioid therapy. The primary adjuvant analgesics are anticonvulsant and antidepressant medications, but a wide variety of other drugs are also used. To optimize analgesic therapy in patients with neuropathic pain, both opioid and adjuvant analgesics must be used effectively. [ONCOLOGY 15:1435-1453, 2001]

Chronic pain is typically classified as nociceptive (visceral or somatic) or neuropathic, depending on the underlying pathophysiology suggested by the pain. Nociceptive pain involves ongoing activation of pain-sensitive neurons by stimulation of specialized nociceptors from tissue irritation or injury. The visceral/somatic distinction depends on the structures involved. Visceral nociceptive pain stems from injury to the viscera or related structures. It may present as the localized ache of organ capsule damage or the poorly localized cramping of obstructed hollow viscera. Somatic nociceptive pain is related to ongoing damage in somatic tissues, such as the bones, joints, and muscles. It is usually described as throbbing, aching, stabbing, or pressure. Somatic pain syndromes are generally perceived to be highly responsive to opioid therapy.[1]

Types of Neuropathic Pain

Neuropathic pain is related to abnormal somatosensory processes that directly affect the peripheral or central nervous system. These processes either stimulate the pain system or damage nonnociceptive pathways to shift the balance between painful and nonpainful inputs to the central nervous system.[2] Neuropathic pain does not require specific peripheral pain receptor stimulation, although it can be made worse by such stimulation.

Some types of neuropathic injury can produce aching, stabbing, or throbbing pain, but these syndromes often have an unfamiliar quality or sensory distortion. Burning, shooting, and tingling are suggestive of nerve involvement, but not sufficient for the diagnosis. Areas of abnormal sensations are often found on examination, including hypesthesia (a numbness or lessening of feeling), paresthesias (spontaneous abnormal nonpainful sensations such as tingling), dysesthesias (spontaneous abnormal painful sensations such as burning, tingling, or electrical sensations), hyperalgesia (increased perception of painful stimuli), hyperpathia (exaggerated pain response), and allodynia (pain induced by nonpainful stimuli).[3]

Pain can be constant, paroxysmal, or a combination of both. Evidence of neural damage on examination or on electrophysiologic study supports the diagnosis but is not required, because damage to the nervous system can be quite focal and not easily detected.

Cancer can cause neuropathic pain by direct invasion, irritation, or external pressure on peripheral neural structures. In addition, antineoplastic therapies, such as surgery, chemotherapy, and radiation, can damage peripheral nerves and lead to neuropathic pain. In most cases, however, nerve injury occurs in tandem with damage to other structures, and the pain has a mixed pathophysiology, with both somatic and neuropathic components.[4] Given this complexity, all patients must undergo a careful assessment that characterizes the pain, identifies potential etiologies, and clarifies the specific pain syndrome. This assessment then guides the selection of analgesic therapies from among a large number of alternatives.

Treatment Strategies

Opioids

Opioids are the mainstay of the treatment of moderate-to-severe cancer pain, including cancer-related neuropathic pain. In most cases, opioid therapy should be maximized before alternative strategies for neuropathic pain therapy are instituted.[5]

If the first opioid selected yields intolerable side effects without satisfactory analgesia, trials of an alternative opioid (opioid rotation) are often considered. Pain that is poorly responsive to an opioid might also be addressed through trials of alternative systemic therapy (adjuvant analgesics), anesthesiologic and neurosurgical techniques, physical therapy and other physiatric modalities, or psychological interventions.[6]

Adjuvant Analgesics

Adjuvant analgesics are drugs that often have been developed for primary indications other than pain but produce analgesic effects in specific circumstances. Although they are usually classified according to their primary roles, many potentially have powerful effects as neuroactive analgesic medications.

General Principles of Adjuvant Analgesic Use—To appropriately administer adjuvant analgesics, the clinician should become familiar with the approved indications, unapproved but accepted indications, probable mild side effects, potentially serious adverse effects, and specific dosing guidelines for pain management. Knowledge of the pharmacokinetics and usual time-to-effect relationship of specific medications is also useful. Because few adjuvant analgesics have been studied in the medically ill, the information used to develop dosing guidelines for cancer pain is usually extrapolated from other patient populations.

The large variability in mode of action and individual response to most adjuvant analgesics, including those in the same class, supports the utility of sequential trials to identify the most useful drug. In the absence of controlled trials, drug selection usually reflects the clinician’s best judgment about the risks associated with the therapy, the likelihood of analgesia, and the possibility of secondary beneficial effects on symptoms other than pain.

Important principles that help ensure an adequate trial of an adjuvant medication include the following:

  1. Choose each medication carefully for both intended effect and side effects. Antidepressant analgesics are appropriate for patients with pain complicated by depressed mood. The sedative side effects of some medications may help patients who have trouble sleeping.
  2. Ensure that patients have realistic expectations, especially concerning the slow onset of effect, the need for long-term use, the probable development of side effects, and the possibility of tolerance to effects over time.
  3. Begin the use of drugs with known bothersome side effects at a low dose and increase the dose slowly to allow patients to become tolerant to side effects. Doses of drugs with fewer side effects can be increased more rapidly or started at a therapeutic level.
  4. Increase the dose of each medication until the desired effect is achieved, side effects become unmanageable, or high therapeutic drug levels are obtained before calling the trial a failure.
  5. Different classes of drugs can be used concomitantly. To achieve the maximum level of symptom control, the concomitant use of drugs from several classes is frequently necessary.
  6. Be persistent, encouraging, and supportive as treatments are implemented.
Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy